Revisiting acquired aplastic anaemia: current concepts in diagnosis and management

Danielle B. Clucas, Lucy C. Fox, Erica M. Wood, Frank S. Hong, John Gibson, Ashish Bajel, Jeff Szer, Piers Blombery, Zoe K. McQuilten, Devendra Hiwase, Frank Firkin, Merrole F. Cole-Sinclair, on behalf of the Australian Aplastic Anaemia Registry Steering Committee

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Acquired aplastic anaemia is a rare, serious, immunologically mediated bone marrow failure syndrome, characterised by marrow hypoplasia of varying severity and significant pancytopenia. Careful attention and investigation, including molecular testing, is required to confirm the diagnosis and exclude other mimicking conditions, such as inherited bone marrow failure syndromes. In a proportion of patients, the disease evolves to myelodysplasia or acute myeloid leukaemia and in some there is an association with paroxysmal nocturnal haemoglobinuria. The disease has a major impact on patient quality of life. Haemopoietic stem/progenitor cell transplantation for eligible patients with an available donor is the only current curative therapy. Other patients may receive immunosuppression, most commonly with anti-thymocyte globulin and cyclosporin. An initial response to immunosuppression is often encouraging, but relapse is common. Supportive care, including management of transfusion requirements and infections, is central to management. Promising new diagnostic tools and emerging therapies will likely transform approaches to this important, chronic and life-threatening condition.

Original languageEnglish
Pages (from-to)152-159
Number of pages8
JournalInternal Medicine Journal
Volume49
Issue number2
DOIs
Publication statusPublished - 4 Feb 2019

Keywords

  • anaemia
  • anti-thymocyte globulin
  • aplastic
  • blood transfusion
  • bone marrow transplantation
  • pancytopenia

Cite this

Clucas, D. B., Fox, L. C., Wood, E. M., Hong, F. S., Gibson, J., Bajel, A., ... on behalf of the Australian Aplastic Anaemia Registry Steering Committee (2019). Revisiting acquired aplastic anaemia: current concepts in diagnosis and management. Internal Medicine Journal, 49(2), 152-159. https://doi.org/10.1111/imj.14140
Clucas, Danielle B. ; Fox, Lucy C. ; Wood, Erica M. ; Hong, Frank S. ; Gibson, John ; Bajel, Ashish ; Szer, Jeff ; Blombery, Piers ; McQuilten, Zoe K. ; Hiwase, Devendra ; Firkin, Frank ; Cole-Sinclair, Merrole F. ; on behalf of the Australian Aplastic Anaemia Registry Steering Committee. / Revisiting acquired aplastic anaemia: current concepts in diagnosis and management. In: Internal Medicine Journal. 2019 ; Vol. 49, No. 2. pp. 152-159.
@article{6d894952ab2841ad87a979bd57b5f6ac,
title = "Revisiting acquired aplastic anaemia: current concepts in diagnosis and management",
abstract = "Acquired aplastic anaemia is a rare, serious, immunologically mediated bone marrow failure syndrome, characterised by marrow hypoplasia of varying severity and significant pancytopenia. Careful attention and investigation, including molecular testing, is required to confirm the diagnosis and exclude other mimicking conditions, such as inherited bone marrow failure syndromes. In a proportion of patients, the disease evolves to myelodysplasia or acute myeloid leukaemia and in some there is an association with paroxysmal nocturnal haemoglobinuria. The disease has a major impact on patient quality of life. Haemopoietic stem/progenitor cell transplantation for eligible patients with an available donor is the only current curative therapy. Other patients may receive immunosuppression, most commonly with anti-thymocyte globulin and cyclosporin. An initial response to immunosuppression is often encouraging, but relapse is common. Supportive care, including management of transfusion requirements and infections, is central to management. Promising new diagnostic tools and emerging therapies will likely transform approaches to this important, chronic and life-threatening condition.",
keywords = "anaemia, anti-thymocyte globulin, aplastic, blood transfusion, bone marrow transplantation, pancytopenia",
author = "Clucas, {Danielle B.} and Fox, {Lucy C.} and Wood, {Erica M.} and Hong, {Frank S.} and John Gibson and Ashish Bajel and Jeff Szer and Piers Blombery and McQuilten, {Zoe K.} and Devendra Hiwase and Frank Firkin and Cole-Sinclair, {Merrole F.} and {on behalf of the Australian Aplastic Anaemia Registry Steering Committee}",
year = "2019",
month = "2",
day = "4",
doi = "10.1111/imj.14140",
language = "English",
volume = "49",
pages = "152--159",
journal = "Internal Medicine Journal",
issn = "1444-0903",
publisher = "Wiley-Blackwell",
number = "2",

}

Clucas, DB, Fox, LC, Wood, EM, Hong, FS, Gibson, J, Bajel, A, Szer, J, Blombery, P, McQuilten, ZK, Hiwase, D, Firkin, F, Cole-Sinclair, MF & on behalf of the Australian Aplastic Anaemia Registry Steering Committee 2019, 'Revisiting acquired aplastic anaemia: current concepts in diagnosis and management' Internal Medicine Journal, vol. 49, no. 2, pp. 152-159. https://doi.org/10.1111/imj.14140

Revisiting acquired aplastic anaemia: current concepts in diagnosis and management. / Clucas, Danielle B.; Fox, Lucy C.; Wood, Erica M.; Hong, Frank S.; Gibson, John; Bajel, Ashish; Szer, Jeff; Blombery, Piers; McQuilten, Zoe K.; Hiwase, Devendra; Firkin, Frank; Cole-Sinclair, Merrole F.; on behalf of the Australian Aplastic Anaemia Registry Steering Committee.

In: Internal Medicine Journal, Vol. 49, No. 2, 04.02.2019, p. 152-159.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Revisiting acquired aplastic anaemia: current concepts in diagnosis and management

AU - Clucas, Danielle B.

AU - Fox, Lucy C.

AU - Wood, Erica M.

AU - Hong, Frank S.

AU - Gibson, John

AU - Bajel, Ashish

AU - Szer, Jeff

AU - Blombery, Piers

AU - McQuilten, Zoe K.

AU - Hiwase, Devendra

AU - Firkin, Frank

AU - Cole-Sinclair, Merrole F.

AU - on behalf of the Australian Aplastic Anaemia Registry Steering Committee

PY - 2019/2/4

Y1 - 2019/2/4

N2 - Acquired aplastic anaemia is a rare, serious, immunologically mediated bone marrow failure syndrome, characterised by marrow hypoplasia of varying severity and significant pancytopenia. Careful attention and investigation, including molecular testing, is required to confirm the diagnosis and exclude other mimicking conditions, such as inherited bone marrow failure syndromes. In a proportion of patients, the disease evolves to myelodysplasia or acute myeloid leukaemia and in some there is an association with paroxysmal nocturnal haemoglobinuria. The disease has a major impact on patient quality of life. Haemopoietic stem/progenitor cell transplantation for eligible patients with an available donor is the only current curative therapy. Other patients may receive immunosuppression, most commonly with anti-thymocyte globulin and cyclosporin. An initial response to immunosuppression is often encouraging, but relapse is common. Supportive care, including management of transfusion requirements and infections, is central to management. Promising new diagnostic tools and emerging therapies will likely transform approaches to this important, chronic and life-threatening condition.

AB - Acquired aplastic anaemia is a rare, serious, immunologically mediated bone marrow failure syndrome, characterised by marrow hypoplasia of varying severity and significant pancytopenia. Careful attention and investigation, including molecular testing, is required to confirm the diagnosis and exclude other mimicking conditions, such as inherited bone marrow failure syndromes. In a proportion of patients, the disease evolves to myelodysplasia or acute myeloid leukaemia and in some there is an association with paroxysmal nocturnal haemoglobinuria. The disease has a major impact on patient quality of life. Haemopoietic stem/progenitor cell transplantation for eligible patients with an available donor is the only current curative therapy. Other patients may receive immunosuppression, most commonly with anti-thymocyte globulin and cyclosporin. An initial response to immunosuppression is often encouraging, but relapse is common. Supportive care, including management of transfusion requirements and infections, is central to management. Promising new diagnostic tools and emerging therapies will likely transform approaches to this important, chronic and life-threatening condition.

KW - anaemia

KW - anti-thymocyte globulin

KW - aplastic

KW - blood transfusion

KW - bone marrow transplantation

KW - pancytopenia

UR - http://www.scopus.com/inward/record.url?scp=85061392191&partnerID=8YFLogxK

U2 - 10.1111/imj.14140

DO - 10.1111/imj.14140

M3 - Review Article

VL - 49

SP - 152

EP - 159

JO - Internal Medicine Journal

JF - Internal Medicine Journal

SN - 1444-0903

IS - 2

ER -